Do you want to read an article? Please log in or register.
QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin
Viral Infections, Non-HIV
Related content
Viral Infections, Non-HIV
Clinical outcomes and adverse events in patients hospitalised with COVID -19, treated with off- label hydroxychloroquine and azithromycin
Br J Clin Pharmacol.
Kelly M, O'Connor R, Townsend L, Coghlan M, Relihan E, Moriarty M, Carr B, Melanophy G, Doyle C, Bannan C, O'Riordan R, Merry C, Clarke S, Bergin C
doi: 10.1111/bcp.14482.
Viral Infections, Non-HIV
Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State
JAMA.
Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, Weinberg P, Kirkwood J, Muse A, DeHovitz J, Blog DS, Hutton B, Holtgrave DR, Zucker HA
doi: 10.1001/jama.2020.8630.
Viral Infections, Non-HIV
Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial
Lancet.
Furtado RHM, Berwanger O, Fonseca HA, Corrêa TD, Ferraz LR, Lapa MG, Zampieri FG, Veiga VC, Azevedo LCP, Rosa RG, Lopes RD, Avezum A, Manoel ALO, Piza FMT, Martins PA, Lisboa TC, Pereira AJ, Olivato GB, Dantas VCS, Milan EP, Gebara OCE, Amazonas RB, Oliveira MB, Soares RVP, Moia DDF, Piano LPA, Castilho K, Momesso RGRAP, Schettino GPP, Rizzo LV, Neto AS, Machado FR, Cavalcanti AB, COALITION COVID-19 Brazil II Investigators
doi: 10.1016/S0140-6736(20)31862-6.
RECOMMENDED
Viral Infections, Non-HIV
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Martin Frey, Faculty Member
N Engl J Med
Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, Damiani LP, Marcadenti A, Kawano-Dourado L, Lisboa T, Junqueira DLM, de Barros E Silva PGM, Tramujas L, Abreu-Silva EO, Laranjeira LN, Soares AT, Echenique LS, Pereira AJ, Freitas FGR, Gebara OCE, Dantas VCS, Furtado RHM, Milan EP, Golin NA, Cardoso FF, Maia IS, Hoffmann Filho CR, Kormann APM, Amazonas RB, Bocchi de Oliveira MF, Serpa-Neto A, Falavigna M, Lopes RD, Machado FR, Berwanger O, Coalition Covid-19 Brazil I Investigators.
doi: 10.1056/NEJMoa2019014
Viral Infections, Non-HIV
Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review
Ann Intern Med.
Hernandez AV, Roman YM, Pasupuleti V, Barboza JJ, White CM
doi: 10.7326/M20-2496.
Viral Infections, Non-HIV
Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring
J Am Heart Assoc.
Ramireddy A, Chugh H, Reinier K, Ebinger J, Park E, Thompson M, Cingolani E, Cheng S, Marban E, Albert CM, Chugh SS
doi: 10.1161/JAHA.120.017144.
Viral Infections, Non-HIV
Real-world Effect of Monoclonal Antibody Treatment in COVID-19 Patients in a Diverse Population in the United States
Open Forum Infect Dis
Rainwater-Lovett K, Redd JT, Stewart MA, Calles NE, Cluff T, Fang M, Panaggio MJ, Lambrou AS, Thornhill JK, Bradburne C, Imbriale S, Freeman JD, Anderson M, Kadlec RP
doi: 10.1093/ofid/ofab398
Viral Infections, Non-HIV
A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in Coronavirus Disease-19 (COVID-19)
Int J Rheum Dis.
Shah S, Das S, Jain A, Misra DP, Negi VS
doi: 10.1111/1756-185X.13842.
Viral Infections, Non-HIV
Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports
Br J Clin Pharmacol.
Goldman A, Bomze D, Dankner R, Hod H, Meirson T, Boursi B, Maor E
doi: 10.1111/bcp.14546.